Telix Pharmaceuticals (ASX:TLX), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or 'molecularly- targeted radiation' (MTR), has announced it has entered into a strategic collaboration agreement with GenesisCare.
GenesisCare is the largest private provider of oncology services in Australia and Europe.
The agreement covers three major collaboration areas.
The first is that the companies have established a preferred clinical provider relationship for running radiation oncology studies in Australia for the inclusion of patients into Telix’s global multi-centre trials in neuro-oncology and urologic oncology.
The second is that they will partner to deliver compassionate use access to Telix’s glioblastoma therapy program across GenesisCare's patient network.
The companies will also jointly explore the commercial potential of Telix’s products in China.
According to Telix CEO Christian Behrenbruch, “GenesisCare is a unique organisation that has both patient access and geographic reach in radiation oncology. The kind of products that Telix is developing are a natural fit for the GenesisCare clinical network, both in terms of trials to support product development but also eventual product roll-out.”
“We see strategic collaborations with companies like Telix as a way to advance clinical trials and make proven new treatments available more quickly – ultimately to improve life outcomes for patients," said GenesisCare CEO Dan Collins.
"Healthcare access for all is also very important to us, and the compassionate-use program as part of this agreement will be life-changing for the patients involved. We look forward to a long partnership with Telix.”